U.S. Contract Research Organization (CROs) Market,
The U.S. Contract Research Organization (CROs) Market, by Therapeutic Application (Respiratory Disorders, Oncology, Central Nervous System Diseases, Cardiovascular Diseases, Metabolic Disorders, Infectious Diseases, Immunological Disorders, and Others), by Service Type (Early Phase I – IIa, Drug Discovery, Phase IIa – III, Preclinical studies, Drug Development, Phase IIIb – IV, Monitoring, Medical Writing and Coding, Biomarker Discovery, Clinical Data Management, Site Management, Bio-statistics, and Protocol Development), and by Size of CRO (Small Size, Medium Size, and Large Size), had a market valuation of US$ 12,174.4 million in 2019, and is forecast to manifest a CAGR of 9.4 percent over the forecast period (2019-2027), as mentioned in a new report published by Coherent Market Insights.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/3179
Clinical trial management software is developed and modified by a number of healthcare IT organizations around the world. Customized software is available to handle clinical trial data based on the needs of the client and the research procedure. Clinical Research Management, Project Setup, eCRFs, Financials, Visit Tracking & Data Capture, Study Data Management, and Revenue Management are all practical aspects of the OnCore clinical trial management system, according to a study undertaken by the University of Minnesota and University of Michigan in 2018. Over the forecast period, this is expected to be one of the major factors driving growth of the U.S. contract research organization (CROs) market.
Browse 09 Market Data Tables and 27 Figures spread through 301 Pages and in-depth TOC on “U.S. Contract Research Organization (CROs) Market, by Therapeutic Application (Respiratory Disorders, Oncology, Central Nervous System Diseases, Cardiovascular Diseases, Metabolic Disorders, Infectious Diseases, Immunological Disorders, and Others), by Service Type (Early Phase I – IIa, Drug Discovery, Phase IIa – III, Preclinical studies, Drug Development, Phase IIIb – IV, Monitoring, Medical Writing and Coding, Biomarker Discovery, Clinical Data Management, Site Management, Bio-statistics, and Protocol Development), and by Size of CRO (Small Size, Medium Size, and Large Size), – Global Forecast to 2027”
Increased R&D spending and increased outsourcing are driving the growth of the U.S. contract research organization (CROs) market. This is due to a change in the market’s emphasis on the advancement of therapeutics for genetic diseases, with more biopharmaceutical companies focused on rare diseases. As a result, the research and development spending in the healthcare sector is projected to fuel the growth of the U.S. contract research organization (CRO) market over the forecast period.
As per the Pharmaceutical Research and Manufacturers of America (PhRMA), pharmaceutical and biotechnology firms spent about US$ 62.2 billion on research and development in 2018, up from US$ 55.8 billion in 2017, accounting for the bulk of all biopharmaceutical R&D spending in the US. In recent years, increased research and development spending has resulted in a rise in the number of drug approvals. As per the FDA data, approximately 59 new drugs were approved in 2018, relative to 46 drugs in 2017. Significant players in the CRO market are expected to use inorganic techniques such as acquisitions and partnerships to propel the U.S. contract research organization (CRO) market.
ICON plc, Medpace, Pharmaceutical Product Development, LLC (PPD), PRA Health Sciences, Syneos Health, UBC, and Veeva Systems joined together in March 2018 to launch Align Clinical CRO, a new business standards association with supporters and CROs to collaborate on clinical trials. In June 2018, LabCorp also purchased Sciformix Corporation, a research process consulting firm that specializes in pharmacovigilance and regulatory technologies for biopharmaceutical and medical device companies.
Key Takeaways
The market for U.S. contract research organizations (CROs) is projected to rise at a 9.4% CAGR from 2019 to 2027, owing to rising demand for advanced clinical trial services and an increase in the number of clinical trials. The Early Phase I – IIa segment is expected to grow at the fastest rate over the forecast period. LabCorp launched a dedicated offering for biotech, medical device, and diagnostics businesses in 2018. Research programs, such as nonclinical and first-in-human trials, Phase I development, central laboratory services, and regulatory and market access consultancy, are also part of the new service portfolio.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/3179
During the forecast period, technological innovation in the field of clinical testing to increase clinical trial performance and effectiveness is projected to boost the monitoring segment growth in the U.S. contract research organization (CRO) market. IQVIA RIM Smart, an advanced, cloud-based, end-to-end regulatory information management system for managing a product portfolio’s full regulatory lifecycle, was launched in February 2019 by IQVIA Holdings Inc. The framework is intended to boost enforcement consistency by increasing speed and reliability.
Key players contributing in the U.S. contract research organization (CRO) market are Amarex Clinical Research LLC, WCCT Global Inc., RHO, Inc., Spaulding Clinical Research, BioClinica Inc., Absolute Research Solutions, Comparative Biosciences, Inc., Theorem Clinical Research, Linical Accelovance, Pharm-Olam, CPC Clinical Research, CMIC Holdings Co., Ltd, Envigo, Wuxi Apptec, Pharmaceutical Product Development (PPD), PSI, Grayline, Integrium, LLC, Novum, Shin Nippon Biomedical Laboratories, Ltd., MedTrials, Cmed, Clindatrix, Inc., ICON Public Limited Corporation, Medpace Holdings, Inc, Clinipace, EPS International, Axis Clinicals LLC, AlcheraBio LLC, Accumedix, Inc., Pharmaron, Axiom Real-Time Metrics, Neurovasc Preclinical Services, Inc., BioPharma Services Inc., Celerion, CATO Research LLC, and Arianne Corporation.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837